The current therapeutic cancer vaccines landscape in non‐small cell lung cancer
International Journal of Cancer · 2024-12 · 155 (11) · 1909-1927
DOI: 10.1002/ijc.35088 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Cancer, online erschienen am 07.08.2024. Verfasst von Shaoyi Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Peking University People's Hospital, Beijing, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Cancer Vaccines, Lung Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 153 Literaturangaben. Gefördert von: Beijing Nova Program, Peking University People's Hospital Research and Development Funds, Research Unit of Intelligence Diagnosis and Treatment in Early Non-small Cell Lung Cancer, Chinese Academy of Medical Sciences.
Abstract (Originalsprache)
Currently, conventional immunotherapies for the treatment of non‐small cell lung cancer (NSCLC) have low response rates and benefit only a minority of patients, particularly those with advanced disease, so novel therapeutic strategies are urgent deeded. Therapeutic cancer vaccines, a form of active immunotherapy, harness potential to activate the adaptive immune system against tumor cells via antigen cross‐presentation. Cancer vaccines can establish enduring immune memory and guard against recurrences. Vaccine‐induced tumor cell death prompts antigen epitope spreading, activating functional T cells and thereby sustaining a cancer‐immunity cycle. The success of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has rendered cancer vaccines a promising avenue, especially when combined with immunotherapy or chemoradiotherapy for NSCLC. This review delves into the intricate antitumor immune mechanisms underlying therapeutic cancer vaccines, enumerates the tumor antigen spectrum of NSCLC, discusses different cancer vaccines progress and summarizes relevant clinical trials. Additionally, we analyze the combination strategies, current limitations, and future prospects of cancer vaccines in NSCLC treatment, aiming to offer fresh insights for their clinical application in managing NSCLC. Overall, cancer vaccines offer promising potential for NSCLC treatment, particularly combining with chemoradiotherapy or immunotherapy could further improve survival in advanced patients. Exploring inhaled vaccines or prophylactic vaccines represents a crucial research avenue.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Peking University People's Hospital, Beijing, China.
- Thoracic Oncology Institute, Peking University People's Hospital Thoracic Oncology Institute & Research Unit of Intelligence Diagnosis and Treatment in Early Non-small Cell Lung Cancer, Beijing, China.
- Institute of Advanced Clinical Medicine, Peking University, Beijing, China.
ORCID-Profile: Kezhong Chen, Mantang Qiu
Förderung
- Beijing Nova Program
- Peking University People's Hospital Research and Development Funds
- Research Unit of Intelligence Diagnosis and Treatment in Early Non-small Cell Lung Cancer, Chinese Academy of Medical Sciences
- National Key R&D Program of China
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Chen, S., Cheng, S., Cai, J., Liu, Z., Li, H., Wang, P., Li, Y., Yang, F., Chen, K., & Qiu, M. (2024). The current therapeutic cancer vaccines landscape in non‐small cell lung cancer. International Journal of Cancer, 155(11), 1909-1927. https://doi.org/10.1002/ijc.35088
Vancouver
Chen S, Cheng S, Cai J, Liu Z, Li H, Wang P, et al. The current therapeutic cancer vaccines landscape in non‐small cell lung cancer. International Journal of Cancer. 2024;155(11):1909-1927. doi:10.1002/ijc.35088
BibTeX
@article{Chen2024,
author = {Chen, Shaoyi and Cheng, Sida and Cai, Jingsheng and Liu, Zheng and Li, Haoran and Wang, Peiyu and Li, Yun and Yang, Fan and Chen, Kezhong and Qiu, Mantang},
title = {The current therapeutic cancer vaccines landscape in non‐small cell lung cancer},
journal = {International Journal of Cancer},
year = {2024},
volume = {155},
number = {11},
pages = {1909--1927},
doi = {10.1002/ijc.35088}
}
EUVIMED